Market Analysis - Global Pharmacovigilance 2018
Conference Series llc LTD warmly invites all the participants across the world to “12th Global Pharmacovigilance & Clinical Trail Summit” scheduled on July 16-17, 2018 in Sydney, Australia. This conference provides a forum for interaction among attendees with discussion involving discovery of a new drug, Challenges in drug development, Pre-Clinical and Clinical trial reports, Case Studies, Pharmacovigilance, Biosimilar and Biologistics and its eye on new drug regulatory approvals. Session discussions focus on discussions about approaches and innovations for Patient Benefit Risk Management in Pharma, Biotech and Health care Industry.
This is a 2 day Mega Event offering Exhibition, at venue to showcase the new and emerging technologies with Keynote presentation, Oral talks, Poster presentations and Exhibitions.
Why to Attend???
To meet your targeted audience in the Series of Pharmacovigilance 2018 Conference with a largest assemblage of participants from the Pharma, Clinical, Healthcare and Regulatory community providing an international and non-biased platform for professionals working in early discovery and preclinical research to exchange ideas on best practice and share case studies on innovation within the area alarming on Medication Safety.
It is an Unique Opportunity for Advertisers and Sponsors at this International event.
Pharmacovigilance (PV) Market Analysis by Clinical Trial Phase:
The global pharmacovigilance (PV) market is projected to reach 10.27 billion USD by 2025. The market is expected to see a growth at 13.1% CAGR owing to increasing incidence of Adverse Drug reaction. The key driver for the growth of pharmacovigilance market is ADR’s. In 2015, the U.S. FDA received almost 253,017 serious adverse events and 44,693 deaths associated with adverse drug reactions (ADRs). This shows the possible demand for instigating safety and pharmacovigilance services.
Rising demand for drugs have been significantly amplified and the need for novel therapeutics development via extensive clinical trials, which is further expected to serve this market with lucrative opportunities. North America region held the largest share of the pharmacovigilance and drug safety software market in 2014. However, Asian and Latin American countries symbolize high growth markets. This is owing to a rise in research outsourcing by pharmaceutical giants and growing public and private investments in pharmaceutical R&D in these emerging nations.
Major pharmaceutical companies are involved in extensive R&D initiatives for development of innovative therapeutic molecules. This has resulted in increased rate of drug development. Manufacturers are now focusing on remodelling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for PV services.
In April 2017, Accenture entered in a collaborative agreement with BioCelebrate to develop a platform for aggregating and analyzing clinical information for improvement in drug developing efficiency, thus enhancing its R&D capabilities. These factors are anticipated to fuel the market growth. North America region held the largest share of the pharmacovigilance and drug safety software market in 2014. However, Asian and Latin American countries symbolize high growth markets. This is owing to a rise in research outsourcing by pharmaceutical giants and growing public and private investments in pharmaceutical R&D in these emerging nations.
Global pharmacovigilance market, by clinical trials, 2012 – 2020 (USD Million)